Last reviewed · How we verify
DAXI for injection 250 U
DAXI is a botulinum toxin type A formulation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.
DAXI is a botulinum toxin type A formulation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions. Used for Glabellar lines (frown lines) in adults, Cervical dystonia.
At a glance
| Generic name | DAXI for injection 250 U |
|---|---|
| Sponsor | Revance Therapeutics, Inc. |
| Drug class | Botulinum toxin type A |
| Target | SNARE complex (acetylcholine release machinery at neuromuscular junction) |
| Modality | Biologic |
| Therapeutic area | Aesthetics / Neurology |
| Phase | Phase 2 |
Mechanism of action
DAXI (DaxibotulinumtoxinA) is a novel botulinum toxin serotype A product engineered with a proprietary peptide excipient (RTP004) designed to enhance potency and duration of action. It works by cleaving SNARE proteins at the neuromuscular junction, preventing acetylcholine vesicle release and thereby reducing unwanted muscle contractions. The formulation aims to provide longer-lasting effects compared to existing botulinum toxin products.
Approved indications
- Glabellar lines (frown lines) in adults
- Cervical dystonia
Common side effects
- Headache
- Injection site reactions
- Muscle weakness
- Eyelid ptosis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DAXI for injection 250 U CI brief — competitive landscape report
- DAXI for injection 250 U updates RSS · CI watch RSS
- Revance Therapeutics, Inc. portfolio CI